Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to Sell

StockNews.com cut shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research note released on Monday.

A number of other analysts have also recently weighed in on the stock. Mizuho assumed coverage on shares of Kura Oncology in a report on Friday, December 22nd. They set a buy rating and a $26.00 price objective on the stock. Wedbush reissued an outperform rating and set a $37.00 price objective on shares of Kura Oncology in a report on Wednesday, February 28th. JMP Securities raised their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a market outperform rating in a report on Wednesday, January 31st. Finally, HC Wainwright reissued a buy rating and set a $32.00 price objective on shares of Kura Oncology in a report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $28.28.

Kura Oncology Stock Down 2.4 %

Shares of Kura Oncology stock opened at $19.01 on Monday. Kura Oncology has a 52-week low of $7.41 and a 52-week high of $24.17. The company has a 50 day moving average of $20.97 and a 200 day moving average of $15.02. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.45 billion, a P/E ratio of -9.14 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. During the same quarter in the previous year, the company posted ($0.49) earnings per share. As a group, research analysts forecast that Kura Oncology will post -2.35 EPS for the current fiscal year.

Insider Activity

In other news, SVP Thomas James Doyle sold 2,318 shares of Kura Oncology stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the transaction, the senior vice president now directly owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Kura Oncology news, SVP Thomas James Doyle sold 2,318 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the transaction, the senior vice president now directly owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kathleen Ford sold 1,496 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the transaction, the chief operating officer now directly owns 21,602 shares in the company, valued at $384,515.60. The disclosure for this sale can be found here. Insiders have sold 96,919 shares of company stock valued at $1,946,415 in the last ninety days. 5.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently bought and sold shares of the company. US Bancorp DE increased its stake in Kura Oncology by 45.0% in the 4th quarter. US Bancorp DE now owns 2,097 shares of the company’s stock valued at $30,000 after buying an additional 651 shares during the period. Legal & General Group Plc increased its stake in Kura Oncology by 4.0% in the 4th quarter. Legal & General Group Plc now owns 22,373 shares of the company’s stock valued at $278,000 after buying an additional 857 shares during the period. Guggenheim Capital LLC boosted its position in shares of Kura Oncology by 3.8% during the 1st quarter. Guggenheim Capital LLC now owns 24,671 shares of the company’s stock worth $397,000 after purchasing an additional 914 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Kura Oncology by 2.7% during the 4th quarter. MetLife Investment Management LLC now owns 35,896 shares of the company’s stock worth $445,000 after purchasing an additional 946 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Kura Oncology by 3.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 27,845 shares of the company’s stock worth $400,000 after purchasing an additional 974 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.